Evidence map›Paper›PMID 41435207›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma.

Zezhong Ye, Reza Mojahed-Yazdi, Anna Zapaishchykova, Divyanshu Tak, Maryam Mahootiha, Juan Carlos Climent Pardo, John Zielke, Yining Zha, Christian Guthier, Roy B Tishler and 11 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
  4. Redefining oropharyngeal cancer in the HPV era: integrating precision medicine and immunotherapeutic frontiers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Zezhong YeArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.
Reza Mojahed-YazdiArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.
Anna ZapaishchykovaArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.ORCID 0000-0001-6860-9160
Divyanshu TakArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.ORCID 0009-0003-4183-209X
Maryam MahootihaArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.
Juan Carlos Climent PardoArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.ORCID 0009-0007-9110-2043
John ZielkeArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.ORCID 0000-0002-8655-3508
Yining ZhaArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.ORCID 0009-0000-7653-3223
Christian GuthierArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.
Roy B TishlerDepartment of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Danielle N MargalitDepartment of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-8281-0829
Jonathan D SchoenfeldDepartment of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-5119-0401
Robert I HaddadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0003-1413-0079
Ravindra UppaluriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Benjamin Haibe-KainsDepartment of Medical Biophysics, University Health Network, Toronto, ON, Canada.
Clifton D FullerDivision of Radiation Oncology, Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-5264-3994
Mohamed NaserDivision of Radiation Oncology, Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-1020-4966
Barbara A BurtnessDepartment of Medicine and Yale Cancer Center, Yale University School of Medicine and Yale Cancer Center, New Haven, CT.ORCID 0000-0003-4660-1859
Hugo J W L AertsArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.
Frank HoebersArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.
Benjamin H KannArtificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, MA.ORCID 0000-0002-4313-2754

Funding

Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI KEITH LLOYD LIGON · 2013 to 2026
$33.5M
The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
Shared Resource Core 2: Clinical Artificial Intelligence CoreU54CA274516 · NCI · DANA-FARBER CANCER INST · PI Ross I. Berbeco · 2023 to 2026
$8.1M
Quantitative Radiomics System Decoding the Tumor PhenotypeU24CA194354 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.5M
Genotype and Imaging Phenotype Biomarkers in Lung CancerU01CA190234 · NCI · DANA-FARBER CANCER INST · PI AERTS, HUGO, QUACKENBUSH, JOHN · 2015 to 2019
$3.3M
Harvard MD Anderson Collaborative to Reduce LyMphatic MOrbidity in Head and Neck Cancer with Artificial Intelligence (HARMONiC-AI)R01DE034780 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Clifton David Fuller, Katherine Arnold Hutcheson · 2025 to 2026
$1.4M
Development of an artificial intelligence-driven, imaging-based platform for pretreatment identification of extranodal extension in head and neck cancerK08DE030216 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · PI KANN, BENJAMIN HARRIS · 2021 to 2025
$841k
NCI NIH HHS P50 CA165962NCI NIH HHS U01 CA190234NCI NIH HHS U01 CA209414NCI NIH HHS U24 CA194354NCI NIH HHS U54 CA274516NIDCR NIH HHS K08 DE030216NIDCR NIH HHS R01 DE034780
6 · The paper itself

Abstract

purposeExtranodal extension (ENE) is a biomarker in oropharyngeal carcinoma (OPC) but can only be diagnosed via surgical pathology. We applied an automated artificial intelligence (AI) imaging platform integrating lymph node autosegmentation with ENE prediction to determine the prognostic value of the number of predicted ENE nodes. MATERIALS AND

methodsWe conducted a multisite, retrospective study of 1,733 OPC patients with pretreatment computed tomography who underwent definitive radiation therapy across three institutions. Malignant lymph nodes were segmented using a validated deep learning auto-segmentation model, and segmented lymph nodes were sequentially processed with a validated ENE prediction model to calculate number of nodes with AI-predicted ENE (AI-ENE) per patient. We evaluated associations of AI-ENE with disease outcomes using site-stratified, multivariable Cox regression, adjusting for human papillomavirus (HPV) status, smoking pack-years, tumor and nodal stage, age, and sex. We evaluated risk-stratification improvement when incorporating AI-ENE into the Radiation Therapy Oncology Group (RTOG)-0129 risk groupings and derived American Joint Committee on Cancer (AJCC) 8th edition staging with Uno C-indices and decision curve analyses.

resultsOverall, median AI-ENE node number was 1 (range, 0-6). AI-ENE node number was independently associated with poorer distant control (DC; hazard ratio [HR], 1.44 [95% CI, 1.23 to 1.69];

conclusionAutomated, AI-ENE node number is a novel risk factor for OPC that may better inform pretreatment risk stratification and decision-making.

Indexed as

Extranodal ExtensionLymph NodesOropharyngeal NeoplasmsAdultAgedArtificial IntelligenceFemaleHumansLymphatic MetastasisMaleMiddle AgedPrognosisRetrospective StudiesRisk AssessmentTomography, X-Ray Computed

Identifiers

PMID41435207
PMCPMC12826331

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.